Abstract
Six of the patients were treated with oral warfarin, two because of implanted heart valves (international normalized ratio, INR=3.3), one because of atrial fibrillation (INR= 2.3), two because of a previously malfunctioning jugular cathether (INR=1.6), and one because of previous pulmonary embolism and a positive lupus anticoagulant (INR= 2.3). The haemoglobin value was stable, and the dose of erythropoietin and iron supplement were kept unchanged the last 2 weeks prior to the study. Patients receiving acetylsalicylic acid treatment were excluded from the study. Other exclusion criteria were clinical signs of infection and disseminated malignant disease. None of the patients had bleeding disorders. The protocol was approved by the Regional Ethics Committee and informed consent was obtained from all the patients according to the Helsinki declaration.
Dialysis procedure
Dalteparin was given as a single bolus dose into the arterial line at start of dialysis. The mean applied dalteparin dose at the start of the study was 60.9±19.3 IU/kg in the patient group receiving warfarin and 69.5±11.5 IU/kg in those without oral anticoagulation. The dialysis sessions were 4 h three times per week in seven patients and 4.5 or 5 h three times per week in five patients. The dialyser used was F6 HPS, Fresenius, Germany, (polysulphone hollow-fibre filter) for at least 1 week before and during the study. Bicarbonate dialysate was used in all patients. During 1-2 weeks prior to the study (run-in period) the dialyser and the bubble trap A B Fig. 1 . The one-exponential relationship between clotting in the were checked at the end of each dialysis session to ensure bubble trap and anti-FXa activity (IE/ml ). The correlation is that there was no clot formation and the dalteparin dose statistically highly significant both in the six patients without warfawas kept unchanged. The blood flow rate varied between rin (R=0.67, A) and in the six patients receiving warfarin, where 230 and 300 ml/min, but was kept close to constant within the curve is displaced to the left (R=0.32, B). each patient. Blood flow was recorded by the regular dialysis machine flowmeter in the dialysis machine. The dialysate flow was kept constant at 500 ml/min. platelets, white cell count, INR, and urea were measured at the start and at the end of the dialysis sessions. Anti-FXa activity was measured after 1, 3 and 4 h in each
Study design
of the 84 dialysis sessions. Blood for anti-FXa was collected into tubes containing citrate and cooled in an ice-water mix To examine the relationship between anticoagulant effect of before centrifuging at 4°C at 2500 g for 30 min. dalteparin and intradialytic clinical clotting the dalteparin dose was gradually tapered in subsequent dialysis sessions.
A total of 84 HD sessions were studied in 12 patients over Laboratory methods a period of 3 weeks in eight patients and 1 week in four patients. The regularly applied dose of dalteparin was given Anti-FXa activity was measured with a chromogenic assay in the first session and then reduced by 25% for each session (CoatestB, Chromogenix AB, Mö lndal, Sweden). down to 50% if no clotting was observed. Clinical clotting was evaluated by visual inspection after blood draining of Statistics the air trap every hour (1, no clotting in the trap; 2, fibrinous ring; 3, clot formation and 4, coagulated system) and by In order to estimate the effect of actual dialysis time and visual inspection of the dialyser at the end of each session anti-FXa activity on the odds of getting coagulation (defined (1, clean filter; 2, a few blood stripes (affecting less than 5% as clotting grade 2 and 3), a logistic regression model of of the fibres seen at the surface of the dialyser); 3, many repeated measurements was adopted (there were several blood stripes (affecting more than 5% of the fibres) and 4, measurements per patient). Since no clotting was found after coagulated filter). If clinical signs of clotting grade 3 or 4 1 h only data from 3 and 4 h after the start of dialysis were were observed, the dalteparin dose was increased by one step included in this analysis. SAS version 6.12 (SAS Institute, (25% of the initial dose). Clinical clotting was compared to Cary, NC ) was used for the calculations. The relationship simultaneously measured anti-FXa activity, Hb, Hct, platelet between clinical clotting and anti-FXa activity was assessed count, blood flow, and ultrafiltration rate.
by one-way analysis of variance by use of one-exponential decay relationship with a computer-based statistical software program, Graph Pad Prism, CA, US. In order to evaluate
Blood sampling
the relationship between anti-FXa activity and dalteparin dose (IU/kg), a linear regression model was performed Blood specimens were taken from the arterial line after lowering the blood flow to 100 ml/min for 1 min. Hb, Hct, (Statistical Software, SPSS). A P value of <0.05 was consid- by 0.1 IU/ml at a given time of dialysis. The elimination of the anti-FXa activity (dalteparin) B, estimates; S, standard error; OR, odds ratio. The effect of time is a mono-exponential first-order process and thus the of dialysis and anti-FXa activity on the odds of clotting estimated half-life is assumed to be dose independent [11, 12] . by logistic regression model with repeated measurements.
We calculated the anti-FXa activity at time zero (C 0 ) and the elimination half life ( T D =ln2/k) calculated ered statistically significant. All statistical tests were two-from the formula C=C 0 · e−kt (k=elimination consided. The results are expressed as mean values ±SD if not stant, t=hours of dialysis and e=2.718) and found otherwise stated.
that the elimination half-life of dalteparin averaged 2.2±0.9 h. The elimination constant was on average calculated to be 0.36±0.15 h. Figure 2 shows a highly significant linear relationship between the anti-FXa activity after 4 h of dialysis and Mean dalteparin bolus dose during the study was dalteparin dose (IU/kg). The data comprises repeated 2665±880 IU or 39±14 IU/kg (84 HD). No episodes measurements in 12 patients following normal and of grade 4 clotting occurred and no session was inter-reduced doses of dalteparin, assuming independence. rupted. Nineteen episodes of grade 3 clinical clotting For anti-FXa levels under the detection limit (0.1 (6% of all observations) were observed. Of these, 18 IU/ml ) the value was calculated assuming first order were in patients without warfarin treatment, only two decline. The regression analysis shows that the antiwith an anti-FXa activity >0.4 IU/ml (0.40 and 0.42 FXa level increases 0.10 IU/ml per 10 IU/kg increase IU/ml respectively), and only one grade 3 episode was in dalteparin dose (confidence interval 0.08-0.12). The observed in patients on warfarin therapy (INR 2.2), three very low values in Figure 2 comprise three in this case the anti-FXa activity was below the detec-different patients treated with warfarin. Although the tion level of 0.1 IU/ml. 32 (19%) observations of minor data are scattered, the biological activity of anti-FXa clotting (grade 2) were observed in non-warfarin-activity during haemodialysis from a given dose of treated patients as compared to 24 (14%) in the dalteparin can be roughly estimated from this plot. A warfarin-treated patients (ns).
Results
dose of at least 50 IU/kg of dalteparin is indicated to Blood flow and ultrafiltration rate were kept within obtain an anti-FXa activity of more than 0.4 IU/ml narrow limits throughout the study to avoid possible after 4 h of dialysis. The dose needed to obtain the influence of these factors on clinical clotting. Hb, Hct, same anticoagulant effect after 5 h of dialysis is indiand platelet count remained unchanged in each patient cated by the broken line. The estimated anti-FXa throughout the study. Blood cell parameters are shown values after 5 h are calculated from the the formula in Table 1 . The factors correlated to clinical clotting C=C 0 · e−kt, assuming first-order decline. in the bubble trap were anti-FXa activity, warfarin Dialysis efficiency was measured as Kt/V in four of treatment, and time on haemodialysis. The relationship the patients. Mean Kt/V before reduction of the daltebetween clotting in the bubble trap and anti-FXa parin dose was 1.3±0.3 and remained unchanged by activity followed one-exponential decay relationship reduction of the dose. with a highly significant correlation (R=0.67, P<0.0001) in patients not receiving oral anticoagulants ( Figure 1A ). Warfarin therapy displaced the Discussion curve to the left (R=0.32, P=0.0003), Figure 1B . The same relationship was found for clotting in the dialyser in the patients who did not receive warfarin (R=0.30, We found that a single dose of dalteparin effectively inhibited significant coagulation in the bubble trap or P=0.026, data not shown). There were too few clotting episodes to study dialyser clotting in the warfarin-dialyser without interruption of any of the 84 dialysis sessions. This was true even when the doses were treated patients. Both time and anti-FXa activity were independently correlated to clotting (grade 2 or 3) in reduced down to 50% of those conventionally applied.
Not surprisingly, a significant correlation was found a logistic regression model of repeated measurements Fig. 2 . The correlation between dalteparin dose and anti-FXa activity (IE/ml ) in 12 patients receiving different doses of dalteparin. The continous line is the regression line for anti-FXa activity after 4 h of dialysis, and the broken line shows the calculated anti-FXa levels after 5 h. Since anti-FXa activity after 4 h of dialysis should be more than 0.4 IU/ml ( lower in patients receiving warfarin) the adequate dalteparin dose is given by the curve. Taking the inter-patient variability into consideration, a safety margin of up to 50% may be applicable. For anti-FXa values under the detection limit (0.1 IU/ml ) a value was estimated assuming a first-order decline. Since time is an independent factor for clotting, the dose of dalteparin should probably be higher than indicated for 5-h dialysis sessions.
between the degree of intradialytic clinical clotting and weighing 70 kg. Alternatively, the actual anti-FXa activity level may be measured after 4 h and the dose the anticoagulant effect measured as anti-FXa activity (Figure 1 ). The risk of major clotting events was close adjusted if necessary.
A standard polysulphone dialyser ( Fresenius F6) to zero with an anti-FXa level higher than 0.4 IU/ml after 4 h of dialysis. This is in agreement with other was used in all sessions in this study. Since dalteparin is removed by dialysis the clearance of small molecules studies on LMW heparins in haemodialysis [13] . Obviously, major clot formations should be avoided of the dialyser may be of importance. High-clearance filters may remove dalteparin at a higher rate and since the dialysis session may be interrupted and the patient may suffer unnecessary blood loss.
result in a more rapid decrease in anticoagulant effect over time. Also variation in 'biocompatibility' between The individual effects of dialysis time and anticoagulant effect may be difficult to assess since an increase different dialysers may modify the anticoagulant effect.
However, such mechanisms could not be elucidated in in dialysis time is accompanied by reduced anticoagulant effect from a single initial dalteparin dose. our study. The elimination half-life of dalteparin averaged 2.2±0.9 h during haemodialysis. Interestingly, Nevertheless, using a logistic regression model of repeated measurements we revealed that dialysis time this is in agreement with the half-life of dalteparin given i.v. to healthy people without renal failure [12] . is an independent risk factor for clinical clotting during haemodialysis. This finding may not be surprising but It is well known that oral anticoagulant treatment may prevent thrombosis in central venous catheters, has not been positively demonstrated by previous studies.
including dialysis catheters [14, 15] . Obviously, oral anticoagulant treatment may also reduce clinical clotThe aim of this study was to relate dalteparin dosage to clinical clotting. Traditionally the dose is arbitrarily ting episodes during haemodialysis, but to our knowledge such an effect has not previously been examined chosen according to clinical experience. We found a highly significant linear relationship between anti-FXa in dialysis patients. In the present study treatment with oral warfarin had a major impact on the degree of level after 4 h of dialysis and dalteparin dose ( Figure  2 ). An estimate of the dose needed to avoid significant clinical clotting episodes. The mean INR for the six patients receiving warfarin was 2.2, indicating that a clinical clotting can be made from this plot. Because of the great biologically interindividual variance in the moderate anticoagulation protects against clotting during haemodialysis. Actually, the patients treated anti-FXa activity (dalteparin) elimination half-life, up to 50% may be added to the estimated dose to ensure with warfarin were in need of a very low dose of dalteparin. In general, anti-FXa activity at the lowest a level of at least 0.4 IU/ml at the end of a 4 h dialysis session. With an added safety margin of 50% to the detection level at the end of dialysis was sufficient to avoid severe clotting in these patients. This may have calculated dose, the recommendation will be about 5000 IU dalteparin for a 4 h session in a patient clinical relevance since many of the dialysis patients
